ADTX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. ADTX has a bad profitability rating. Also its financial health evaluation is rather negative. ADTX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year ADTX has reported negative net income.
ADTX had a negative operating cash flow in the past year.
ADTX had negative earnings in each of the past 5 years.
In the past 5 years ADTX always reported negative operating cash flow.

1.2 Ratios

ADTX has a worse Return On Assets (-357.97%) than 92.38% of its industry peers.

		Industry Rank	Sector Rank
ROA	-357.97%
ROE	N/A
ROIC	N/A

ROA(3y)-152.11%

ROA(5y)-160.9%

ROE(3y)-396.44%

ROE(5y)-345.59%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ADTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADTX has more shares outstanding
The debt/assets ratio for ADTX has been reduced compared to a year ago.

2.2 Solvency

ADTX has an Altman-Z score of -32.13. This is a bad value and indicates that ADTX is not financially healthy and even has some risk of bankruptcy.
ADTX's Altman-Z score of -32.13 is on the low side compared to the rest of the industry. ADTX is outperformed by 88.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-32.13

ROIC/WACCN/A

WACC9.19%

2.3 Liquidity

ADTX has a Current Ratio of 0.02. This is a bad value and indicates that ADTX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.02, ADTX is doing worse than 95.43% of the companies in the same industry.
A Quick Ratio of 0.02 indicates that ADTX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.02, ADTX is doing worse than 95.43% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.02
Quick Ratio	0.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.34% over the past year.
ADTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.17%.
ADTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.

EPS 1Y (TTM)81.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.04%

Revenue 1Y (TTM)-97.17%

Revenue growth 3Y6.8%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-2096.63%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year1584.79%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADTX. No positive earnings are expected for the next year.